Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 21365779)

1.

Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety.

Rosenfeld M, Davis S, Brumback L, Daniel S, Rowbotham R, Johnson R, McNamara S, Jensen R, Barlow C, Ratjen F.

Pediatr Pulmonol. 2011 Jul;46(7):666-71. doi: 10.1002/ppul.21425. Epub 2011 Mar 1.

2.

Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis.

Subbarao P, Balkovec S, Solomon M, Ratjen F.

Pediatr Pulmonol. 2007 May;42(5):471-6.

PMID:
17436328
3.

Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial.

Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, Johnson R, Kronmal R, Davis SD; ISIS Study Group.

JAMA. 2012 Jun 6;307(21):2269-77. doi: 10.1001/jama.2012.5214.

4.

Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial.

Ros M, Casciaro R, Lucca F, Troiani P, Salonini E, Favilli F, Quattrucci S, Sher D, Assael BM.

J Aerosol Med Pulm Drug Deliv. 2014 Apr;27(2):133-7. doi: 10.1089/jamp.2012.1034. Epub 2013 Jun 8.

PMID:
23745525
5.

Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis.

Dellon EP, Donaldson SH, Johnson R, Davis SD.

Pediatr Pulmonol. 2008 Nov;43(11):1100-6. doi: 10.1002/ppul.20909.

PMID:
18828160
6.

Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis.

Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF.

Pediatr Pulmonol. 1996 Feb;21(2):77-83.

PMID:
8882210
7.

[Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis].

Máiz Carro L, Lamas Ferreiro A, Ruiz de Valbuena Maiz M, Wagner Struwing C, Gabilondo Álvarez G, Suárez Cortina L.

Med Clin (Barc). 2012 Feb 4;138(2):57-9. doi: 10.1016/j.medcli.2011.02.022. Epub 2011 Apr 20. Spanish.

PMID:
21511313
8.

Nebulised hypertonic saline for cystic fibrosis.

Wark PA, McDonald V.

Cochrane Database Syst Rev. 2003;(1):CD001506. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD001506.

PMID:
12535409
9.

Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis.

Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, King M, Bye PT.

Thorax. 1997 Oct;52(10):900-3.

10.

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.

Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group.

N Engl J Med. 2006 Jan 19;354(3):229-40.

11.

Nebulised hypertonic saline for cystic fibrosis.

Wark P, McDonald VM.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001506. doi: 10.1002/14651858.CD001506.pub3. Review.

PMID:
19370568
12.

Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis.

Laube BL, Sharpless G, Carson KA, Kelly A, Mogayzel PJ Jr.

BMC Pulm Med. 2011 Sep 6;11:45. doi: 10.1186/1471-2466-11-45.

13.

The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study.

Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, Anderson SD, Bye PT.

Eur Respir J. 1999 Sep;14(3):678-85.

14.

Mucus clearance and lung function in cystic fibrosis with hypertonic saline.

Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC.

N Engl J Med. 2006 Jan 19;354(3):241-50.

15.

Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline.

Subbarao P, Stanojevic S, Brown M, Jensen R, Rosenfeld M, Davis S, Brumback L, Gustafsson P, Ratjen F.

Am J Respir Crit Care Med. 2013 Aug 15;188(4):456-60. doi: 10.1164/rccm.201302-0219OC.

16.

Nebulised hypertonic saline for cystic fibrosis.

Wark PA, McDonald V, Jones AP.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001506. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001506.

PMID:
16034863
17.

Timing of hypertonic saline inhalation for cystic fibrosis.

Elkins M, Dentice R.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD008816. doi: 10.1002/14651858.CD008816.pub2. Review.

PMID:
22336853
18.

Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis.

Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT.

Am J Respir Crit Care Med. 1996 May;153(5):1503-9.

PMID:
8630593
19.

Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.

Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B; Cystic Fibrosis Foundation Therapeutics Development Network.

Pediatr Pulmonol. 2005 Apr;39(4):339-48.

PMID:
15704203
20.

Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function.

Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F.

Thorax. 2010 May;65(5):379-83. doi: 10.1136/thx.2009.125831.

PMID:
20435858
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk